G-Therapeutics raises EUR 36 million to develop novel neuro-stimulation therapy for spinal cord injury
19.04.2016
The TOP 100 Swiss Startup 2015 G-Therapeutics has raised EUR 36 million to develop its novel neuro-stimulation therapy for people with spinal cord injuries.
 Vincent Delattre, co-Founder at G-Therapeutics
|
 |
G-Therapeutics will use the funds to bring a unique, new therapy for improved rehabilitation of spinal-cord injuries from the lab to patients. In particular, the Company is developing a unique, Implantable Neuro-stimulation System for electrical stimulation of specific areas of the spinal cord and will subsequently perform a multi-center clinical study to obtain regulatory approval.
The Swiss-Dutch Company is building further upon the scientific achievements of Professor Grégoire Courtine, who occupies the International Paraplegic Foundation Chair in Spinal Cord Repair, and his colleagues at the Center for Neuro-prosthetics and Brain Mind Institute of EPFL and at the University Hospital of Vaud. For over 15 years, Professor Courtine has been working on unravelling the mechanisms underlying an effective treatment for people with a spinal cord injury affecting the lower limbs. As one of the founders and Chief Scientific Officer of the Company, Professor Courtine comments: "I am delighted that after a decade of dedicated research and all the scientific accomplishments of my team, G-Therapeutics will enable the development of realistic therapeutic solutions for people with spinal cord injury."
2014 the EPFL spin-off was part of the Swiss national startup team in Boston and New York and won 30'000 CHF from Venture Kick. Learn more about the startup in the video interview with co-founder Vincent Delattre:
The Swiss-Dutch Company is building further upon the scientific achievements of Professor Grégoire Courtine, who occupies the International Paraplegic Foundation Chair in Spinal Cord Repair, and his colleagues at the Center for Neuro-prosthetics and Brain Mind Institute of EPFL and at the University Hospital of Vaud. For over 15 years, Professor Courtine has been working on unravelling the mechanisms underlying an effective treatment for people with a spinal cord injury affecting the lower limbs. As one of the founders and Chief Scientific Officer of the Company, Professor Courtine comments: "I am delighted that after a decade of dedicated research and all the scientific accomplishments of my team, G-Therapeutics will enable the development of realistic therapeutic solutions for people with spinal cord injury."
2014 the EPFL spin-off was part of the Swiss national startup team in Boston and New York and won 30'000 CHF from Venture Kick. Learn more about the startup in the video interview with co-founder Vincent Delattre: